Skip to content

Optimized and Personalized Trans-cranial Brain Stimulation in Partial Refractory Epilepsies

Optimized and Personalized Trans-cranial Brain Stimulation in Partial Refractory Epilepsies

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06212609
Acronym
PerEpi2
Enrollment
20
Registered
2024-01-19
Start date
2023-12-01
Completion date
2027-01-01
Last updated
2024-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children, Epilepsy, HR EEG, Pharmacoresistant, tDCS, Transcranial Electric Stimulation

Keywords

Transcranial electric stimulation, tDCS, Epilepsy, pharmacoresistant, HR EEG, children

Brief summary

Epilepsy is one of the most common neurological diseases, affecting between 0.5% and 1% of the general population. Therefore, new diagnostic and treatment methods are having a big impact on society. Epilepsy is also one of the most commonly diagnosed pediatric neurological disorders, with long-term implications for the quality of life of those affected and their relatives. In only two-thirds of cases, seizures can be adequately controlled with anticonvulsant drug therapy. For other patients with a drug-resistant focal epilepsy (up to around 2 million in Europe) epilepsy surgery is currently the most effective treatment. However, only 15-20% of these drug-resistant patients are eligible for epilepsy surgery. This is either because the cortical epileptogenic zone cannot be localized with sufficient precision with standard diagnostic means, or because the epileptogenic zone overlaps meaningful cortical areas, so that it cannot be surgically removed without considerable neurological deficit.

Interventions

OTHERtranscranial electrical stimulation therapy

new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Any patient, male or female aged 1 to 18, with refractory partial epilepsy considered potentially surgical according to the definition of ILAE. Drug-resistant epilepsy can be defined as the failure of adequate therapeutic trials of two antiepileptics (either monotherapy or in combination) so that the patient is free from seizures on a lasting basis. * Any epileptic patient with interictal epileptic spikes on his standard or High Resolution EEG and or on the Magnetoencephalography examination * Any epileptic patient undergoing a structural MRI * Any patient who has agreed to participate in the PerEpi 1 study allowing the optimization of the location of epileptic sources and the modelling of the optimization of the parameters of transcranial electrical stimulation * Patients who have at least 4 seizures per month

Exclusion criteria

* Patient not meeting the age criteria * And/or presenting generalized epilepsy * And/or presenting diffuse interictal peaks and/or presenting a serious alteration of the general condition and vital functions * And/or in the event of refusal by one of the parents or the child * Pregnant, parturient or breastfeeding woman. * Contraindication to the use of mc-tDCS stimulation without seizure

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline of remaining seizure number10 weeksevaluation a new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies during a study allowing to identify a proof of concept, in particular for patients who are not eligible for epilepsy surgery

Countries

France

Contacts

Primary ContactFabrice Wallois, Pr
fabrice.wallois@u-picardie.fr03 22 087775

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026